Korean Circ J.  2012 Apr;42(4):229-230. 10.4070/kcj.2012.42.4.229.

Efonidipine, Another Beauty Relieving the Pressure

• Shin J

• KMID: 2225014
• DOI: http://doi.org/10.4070/kcj.2012.42.4.229

Abstract

No abstract available.

MeSH Terms

Beauty
Dihydropyridines
Nitrophenols
Organophosphorus Compounds
Dihydropyridines
Nitrophenols
Organophosphorus Compounds

Reference

1. Tardif JC. Heart rate as a treatable cardiovascular risk factor. Br Med Bull. 2009. 90:71–84.

2. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005. 366:895–906.

3. Williams B, Lacy PS. CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009. 54:705–713.

4. Komukai M, Tsutsumi T, Ebado M, Takeyama Y. Effect of an L- and T-type calcium channel blocker on 24-hour systolic blood pressure and heart rate in hypertensive patients. Korean Circ J. 2012. 42:231–238.

5. Oh IY, Seo MK, Lee HY, et al. Beneficial effect of efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild-to-moderate essential hypertension. Korean Circ J. 2010. 40:514–519.

6. Sasaki H, Saiki A, Endo K, et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb. 2009. 16:568–575.

7. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008. 372:807–816.

8. Tanaka H, Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev. 2002. 20:81–92.